Tirzepatide: A new treatment option for managing obesity

From autumn 2025, eligible patients living with obesity will be able to begin accessing tirzepatide (Mounjaro®) for weight loss purposes in primary care settings. This does not mean prescriptions will be provided immediately. It means primary care settings can begin discussions with patients about whether tirzepatide is the right option to improve their health through weight loss.

In Hampshire and the Isle of Wight around 1,000 people currently qualify for the medication based on national eligibility criteria – the Hampshire and IOW ICB are working to set up services quickly, however this it will not be available locally until later this year (autumn) – so please don’t contact us just yet as we are unable to help currently. We will contact eligible patients when the ICB allows us.

For further and up-to-date information please see https://www.hantsiow.icb.nhs.uk/weight-loss-support